Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo

Non-alcoholic fatty liver disease (NAFLD) is emerging as the largest burden of chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD that can progress to cirrhosis and hepatocellular carcinoma. Unfortunately, current treatment options for NASH are very l...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of medicinal chemistry 2023-09, Vol.257, p.115510-115510, Article 115510
Hauptverfasser:	Xiang, Cen, Chen, Xiaoxuan, Yao, Jiaping, Yang, Na, Yu, Jiajia, Qiu, Quanyuan, Zhang, Shouqing, Kong, Xiangsun, Zhao, Lianbo, Fan, Zhen-Chuan, Yu, Peng, Teng, Yu-ou
Format:	Artikel
Sprache:	eng
Schlagworte:	GFT505 HepG2 MCD NASH PPAR
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!